It has been reported that the upregulation of CCL5 may promote immune evasion through recruiting Treg cells into tumor lesion and anti-PD-L1 treatment could enhance CCL5-mediated anti-tumor effects in pancreatic ductal adenocarcinoma (Wang et al., 2020). Here, CCL5 is linked to pancreatic ductal adenocarcinoma.